UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ahead of AbbVie’s Rinvoq and Skyrizi three months into its ...

EXTON, PA, June 02, 2025 (GLOBE NEWSWIRE) -- Just over six months into its dual launch across Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (axSpA), UCB’s Bimzelx (bimekizumab ...

Just over six months into its dual launch across Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (axSpA), UCB’s Bimzelx (bimekizumab) is demonstrating meaningful ...

UCB SA's solid buy case is driven by Bimzelx's impressive performance and robust financials despite a temporary 19% EBITDA decline due to product launch investments. Bimzelx, approved for ...

1* BIMZELX was generally well tolerated and no ... Head of Patient Evidence, UCB. "These longer-term data build on the 48-week results, demonstrating maintained response over two years, which ...

Approval is supported by data from the two Phase 3 studies, BE HEARD I and BE HEARD II, in which BIMZELX ® (bimekizumab-bkzx) improved the signs and symptoms of disease vs. placebo at Week 16 ...

Biopharmaceutical company UCB has received US Food and Drug Administration (FDA) approval for BIMZELX (bimekizumab-bkzx) to treat adults with three inflammatory conditions. The product is ...

As of July, the therapy has reached more than 35,000 patients globally, CEO Jean-Christophe Tellier commented in the company’s half-year financial report. During the period, Bimzelx picked up ...

1* BIMZELX was generally well-tolerated over two ... and vulvovaginal mycotic infections. UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery ...